SVRA at a glance
Savara Inc (SVRA, SEC CIK 1160308) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on June 8, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Savara Inc (SVRA) shares worth $222.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $222.8M · +0 vs prior quarter
- Latest 8-K
- Jun 8, 2026
- Item 5.03 · Item 5.07 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No Risk Factors section provided in the submitted excerpt
- No newly added risk factor or trigger identifiable
- No materially updated regulatory, legal, operational, competitive, market, or financial risk disclosed
AI summary of the SVRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Authorized common shares doubled from 300 million to 600 million
- Stockholder-approved amendment effective June 4, 2026 upon Delaware filing
Item 5.07: Submission of Matters to a Vote of Security Holders
- All six director nominees elected, with An van Es-Johansson receiving 158.7M votes for
- Authorized common shares doubled from 300M to 600M, expanding potential equity-financing capacity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 18.9 million additional shares under Savara’s 2024 incentive plan, increasing potential equity dilution
- CFO and Chief Administrative Officer David Lowrance resigns July 15, 2026, citing health reasons
Item 1.01: Entry into a Material Definitive Agreement
- HQ relocation to Yardley, PA (19 W. College Ave); ~10,795 sq ft leased from ML7 Yardley Partners
- Lease term July 1, 2026 – Dec 1, 2031 with 5-year renewal option
AI summaries of SVRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SVRA
Don't miss the next SVRA filing
- Alerts as it files. A push when SVRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SVRA, by share count.
- Ask anything. An AI agent that reads every SVRA filing and answers with sources.
SVRA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Parker Braden C. | F | Sep 24, 2026 | 29,323 | $5.07 |
| Lutz Robert Matthew | A | Jul 15, 2026 | 70,000 | - |
| Lutz Robert Matthew | A | Jul 15, 2026 | 35,000 | - |
| Lowrance David L | M | Jun 22, 2026 | 12,500 | $4.45 |
| Lowrance David L | M | Jun 22, 2026 | 218,750 | $1.51 |
| Lowrance David L | F | Jun 22, 2026 | 60,057 | $5.50 |
| Lowrance David L | M | Jun 22, 2026 | 56,937 | $1.11 |
| Lowrance David L | F | Jun 22, 2026 | 21,682 | $5.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$60.0M | -$103.2M | -$123.5M |
| Net Income | -$54.7M | -$95.9M | -$118.8M |
| Balance Sheet | |||
| Total Assets | $177.6M | $212.9M | $253.4M |
| Equity | $140.4M | $171.4M | $203.1M |
| ROE | -39.0% | -55.9% | -58.5% |
| Per Share | |||
| EPS | $-0.33 | $-0.48 | $-0.53 |
| Cash Flow | |||
| Operating CF | -$51.1M | -$89.1M | -$101.0M |
| CapEx | - | $25K | $22K |
Source: XBRL data in Savara Inc (SVRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SVRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $222.8M |
| Q1 2026 | 26 | $196.4M |
| Q4 2025 | 20 | $209.2M |
| Q3 2025 | 22 | $94.7M |
| Q2 2025 | 21 | $56.0M |
| Q1 2025 | 18 | $45.5M |
| Q4 2024 | 15 | $52.0M |
| Q3 2024 | 14 | $32.2M |
- BlackRock+1.20M (+11%)
- D.E. Shaw & Co+403.1K (+19%)
- Vanguard Portfolio Management LLC+260.4K (+19%)
- Goldman Sachs Group+249.3K (+43%)
- Vanguard Capital Management LLC+148.6K (+2%)
- Morgan Stanley−1.42M (-80%)
- Citadel Advisors LLC−537.7K (-67%)
- Renaissance Technologies LLC−403.8K (-62%)
- State Street Corp−154.3K (-2%)
- Bank of America Corp−67.8K (-12%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SVRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 20, 2026 | - | - | - |
| 8-K | Mar 13, 2026 | - | Analysis | - |
| 10-K | Mar 13, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 17, 2026 | - | - | |
| 8-K | Jan 27, 2026 | - | - | |
| SC 13G | Jan 21, 2026 | - | - | |
| 8-K | Jan 9, 2026 | - | - | |
| 4 | Dec 19, 2025 | - | - | |
| 4 | Dec 16, 2025 | - | - | |
| 4 | Dec 16, 2025 | - | - | |
| 4 | Dec 16, 2025 | - | - | |
| 4 | Dec 16, 2025 | - | - | |
| 4 | Dec 16, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - | |
| 4 | Dec 11, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SVRA SEC filings: frequently asked questions
Which institutions hold SVRA stock?
As of June 30, 2026, the largest Savara Inc (SVRA) holders among the 13F filers tracked by SignalX were BlackRock ($77.0 million), Vanguard Capital Management LLC ($48.9 million), State Street Corp ($40.4 million), D.E. Shaw & Co ($15.5 million), Vanguard Portfolio Management LLC ($10.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did SVRA report in its latest 8-K?
Savara Inc (SVRA) filed an 8-K on June 8, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Authorized common shares doubled from 300 million to 600 million.
What are the latest SVRA SEC filings?
Savara Inc (SVRA) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on June 8, 2026 and a Form 4 insider filing on September 25, 2026.
What is SVRA's SEC CIK number?
Savara Inc (SVRA)'s SEC Central Index Key (CIK) is 1160308. EDGAR lists every SVRA filing under that number.
Ask anything about SVRA
The research agent reads SVRA's filings, financials, insider trades and 13F holders, then answers with sources.